In Re: Restasis - Third-Party Payors Antitrust Litigation

Are you a third-party payor (entities such as employers or insurers with self-funded prescription drug plans) that bought or provided reimbursement for the dry-eye disease drug Restasis between May 1, 2015 to July 31, 2021?

If so, you may be entitled to compensation as a result of this litigation.

Settlement Total
Settlement Total
Eligible Purchase Dates
5/1/15 - through 7/31/21
Eligible Purchase Dates



Background Information

This lawsuit is about claims that Allergan engaged in a monopolization scheme that kept generic versions of Restasis off the market and made Restasis prices higher than they otherwise would have been. The Court has certified this case as a class action. Allergan has settled with End Payor Plaintiffs/Third Party Payors for $30 million.

Settlement Information

Filing Deadline: August 11, 2022

Claims Period and Third Party Payor Class Definition+

Third-party payors are all all entities that from May 1, 2015 to July 31, 2021, paid for and/or provided reimbursement for some or all of the purchase price for Restasis for use by their members, employees, insureds, participants, or beneciaries, where such persons purchased the drug in a pharmacy or received Restasis by mail-order prescription, in the following states: Arizona, Arkansas,* California, Colorado, the District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Utah, West Virginia, and Wisconsin.

* Arkansas purchases, payments, and reimbursements for Restasis must have occurred between May 1, 2015 and July 31, 2017.

Excluded from the class are:

Allergan, its officers, directors, employees, subsidiaries, and affiliates; all federal and state government entities except for cities, towns, municipalities, or counties with self-funded prescription drug plans; all persons or entities who purchased Restasis for purposes of resale or directly from Allergan of its affiliates; fully insured health plans, i.e., plans that purchased insurance covering 100 percent of their reimbursement obligations to members; any “flat copay” consumers who purchased Restasis only via a fixed dollar copayment that does not vary on the basis of the drug’s status as brand or generic; PBMs; and all judges assigned to this case and their chambers staff and any members of the judges’ or chambers staff’s immediate families.


Claim forms are not yet available from the Class Administrator. Class members are not required to sign up with any third-party service in order to participate in the monetary relief, but may instead file their claim directly with the Class Administrator. No-cost assistance will be available from the Class Administrator and Class Counsel during the claims-filing period. For additional information class members may visit  court approved website for this case https://


Receive More Information

Receive more information on this case by completing the form below.